Quick Answer
XBiotech Inc. reported Total Assets of $150.08 million for the year ending 2025.
- XBiotech Inc. showed a decrease of -24.6% in Total Assets from 2024 to 2025.
- This data is from XBiotech Inc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2015: $126.85 million | Q3 2015: $119.05 million | Q1 2016: $101.26 million | Q2 2016: $93.20 million | Q3 2016: $78.29 million | Q1 2017: $87.62 million | Q2 2017: $77.84 million | Q3 2017: $70.67 million | Q1 2018: $58.86 million | Q2 2018: $54.29 million | Q3 2018: $49.24 million | Q1 2019: $39.82 million | Q2 2019: $71.88 million | Q3 2019: $66.64 million | Q1 2020: $358.37 million | Q2 2020: $358.76 million | Q3 2020: $353.39 million | Q1 2021: $355.94 million | Q2 2021: $353.96 million | Q3 2021: $279.52 million | Q1 2022: $270.80 million | Q2 2022: $266.46 million | Q3 2022: $250.83 million | Q1 2023: $242.12 million | Q2 2023: $235.14 million | Q3 2023: $229.60 million | Q1 2024: $227.86 million | Q2 2024: $215.56 million | Q3 2024: $209.85 million | Q1 2025: $181.86 million | Q2 2025: $178.68 million | Q3 2025: $172.42 million.
- Over the full 12 years of available data (2014 to 2025), XBiotech Inc.'s Total Assets has grown by 141.4%.
- Historical annual values: Fiscal year 2025: $150.08 million | Fiscal year 2024: $199.09 million | Fiscal year 2023: $226.62 million | Fiscal year 2022: $246.10 million | Fiscal year 2021: $275.18 million | Fiscal year 2020: $353.74 million | Fiscal year 2019: $816.88 million | Fiscal year 2018: $44.35 million | Fiscal year 2017: $62.97 million | Fiscal year 2016: $67.05 million | Fiscal year 2015: $109.36 million | Fiscal year 2014: $62.18 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: